Tirzepatide 2.5 mg vial (GLP1+GIP)

Tirzepatide 2.5 mg vial - characteristics

Tirzepatide 2.5 mg is a synthetic peptide that is a dual agonist of GIP and GLP-1 receptors. This compound has been extensively studied in the scientific literature in the context of incretin signaling, regulation of glucose metabolism and mechanisms of energy balance control.

What is tirzepatide 2.5 mg and what is its mechanism of action?

Tirzepatide is a single molecule designed to simultaneously activate two incretin receptors:

• GLP-1 receptor (glucagon-like peptide-1 receptor) - associated with glucose-dependent insulin secretion, modulation of glucagon secretion and effects on satiety signaling.

• GIP receptor (glucose-dependent insulinotropic polypeptide receptor) - involved in the regulation of insulin response and metabolic processes.

Dual activation of these pathways distinguishes tirzepatide from classical GLP-1 agonists. This mechanism has been described in detail in clinical trials of the SURPASS program and SURMOUNT, where the molecule's effects on glycemic parameters and body weight were analyzed under controlled study conditions.

Tirzepatide 2.5 mg in clinical models

Published clinical studies have shown that tirzepatide as a class of incretin molecules:

• significantly affects parameters of glucose metabolism (HbA1c),

• Affects mechanisms regulating appetite and energy balance,

• demonstrates the dose dependence of the effect in escalation protocols.

The 2.5 mg dose in the clinical regimens acted as the starting dose in the escalation models, allowing assessment of the body's tolerance and adaptation to further dosage levels.

The difference: tirzepatide 2.5 mg vs 5 mg

In clinical trial documentation:

• tirzepatide 2.5 mg was used as an introductory dose,

• Higher doses (5 mg and above) were analyzed for full metabolic effects.

The evaluation of efficacy in terms of weight reduction was carried out mainly for higher doses under controlled study conditions.

Qualitative information

Offered tirzepatide 2.5 mg is subject to qualitative analysis (e.g., HPLC) to confirm purity and compliance with laboratory specifications.

The product is not a medicinal product or supplement.
Intended for research and analytical applications only.

Data from the SURMOUNT-1 clinical trial

In a randomized phase III clinical trial SURMOUNT-1 (NEJM, 2022) evaluated the effect of tirzepatide on body weight in obese or overweight individuals without diabetes.

The study used a dose escalation scheme beginning with the 2.5 mg, and then increased to target levels (5 mg, 10 mg, 15 mg).

After 72 weeks of follow-up:

• The average weight reduction was about 15% for 5 mg dose,

• about 19.5% for 10 mg dose,

• about 20.9% for 15 mg dose,

• In the placebo group, the reduction was about 3.1%.

In addition, improvements in metabolic parameters were observed, including changes in the lipid profile and indices of glucose metabolism.

It is worth noting that The 2.5 mg dose in clinical trials acted as an introductory dose, used to improve tolerance before reaching higher dosage levels.

Scientific source

Jastreboff AM et al, Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10088547/

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.